Essais cliniques au Canada : cancer du sein

Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada

Recruiting now5 sites

EXCEL will provide online and, where feasible, in-person exercise programs to individuals living with and beyond cancer (ILWBC). Research has shown that targeted programs that include tailored exercise prescriptions are more successful in h…

Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors

Recruiting now1 site

The goal of this randomized controlled pilot study is to assess the feasibility, acceptability, and preliminary effects of the PACHA program designed for women having an adjuvant endocrine therapy (AET) after hormone-sensitive breast cancer…

Cardio-Oncology Rehabilitation Exercise

Recruiting now1 site

Women with breast cancer who are referred to the cardiac rehabilitation program at the Toronto Rehabilitation Institute will be invited to enrol in this observational study. Participants will take part in an established 16-week multimodal c…

What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Surgery

Recruiting now2 sites

This study will look at whether females who have previously had breast surgery and radiation and are undergoing repeat breast surgery require any post operative interventions. The reason the investigators are conducting this study is becaus…

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

Recruiting nowPhase 330 sites

The primary objective of this study is to determine in women with node negative BC ≤3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis. The primary outco…

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Recruiting nowPhase 1/218 sites

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body)…

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting nowPhase 210 sites

This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done…

Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy

Recruiting now23 sites

To de-escalate radiation therapy in women with breast cancer.

FMT in Triple Negative Breast Cancer Guided by ctDNA

Opening soonPhase 1/23 sites

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer, usually treated with chemotherapy and an immune checkpoint blockade (ICB) in the pre-operative or neoadjuvant phase. However, about 35% of tumors do not respond fu…

Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer

Recruiting nowPhase 48 sites

The current standard of care for stage 1 hormone receptor-positive (HR+) breast cancer consists of breast-conserving surgery followed by adjuvant radiotherapy (RT) and endocrine therapy (ET) for at least 5 years. The benefit of adjuvant ET …

Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients

Recruiting now1 site

The investigators propose to use clinically validated patient avatar technology ("PDXovo") that can test multiple drugs against patients' cancers to identify the most promising systemic therapy for each individual.

TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence

Recruiting now3 sites

Triple negative breast cancer (TNBC) is the most aggressive of breast cancers and it is usually treated with chemotherapy even before surgery. In many cases, the chemotherapy completely "melts" the tumor and these patients do well. When the…

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

Recruiting nowPhase 22 sites

This study will evaluate the immune-priming effects of stereotactic body radiation therapy (SBRT) regimen coupled with two injections of pembrolizumab in high-risk primary breast carcinoma prior to neoadjuvant chemotherapy. Preliminary resu…

HER2-PET Imaging in HER2-low Breast Cancers

Recruiting nowPhase 1/21 site

A strategy to target the oncogenic receptor HER2 using a version of the anti-HER2 therapeutic antibody trastuzumab coupled to desferrioxamine (DFO) and radiolabeled with zirconium-89 (\[89Zr\]-DFO-trastuzumab) has been successfully evaluate…

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Recruiting now19 sites

Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of …

Photoacoustic Imaging for Characterizing Breast Masses and Breast Tumor Response to Neoadjuvant Chemotherapy

Recruiting now1 site

Our objective in this pilot study will be to identify PA parameters that can distinguish benign vs. malignant lesions, and also, if PA parameters change with within breast tumors during chemotherapy treatment over time.

Contrast-enhanced Mammography in Women With a Personal History of Breast Cancer and Dense Breast Tissue: Benefit?

Opening soon1 site

This study aims to assess the effectiveness of Contrast-Enhanced Mammography (CEM)as an alternative to traditional ultrasound for breast cancer screening in women with dense breasts and a personal history of breast cancer. CEM combines stan…

Single Pre-Operative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS)

Recruiting now2 sites

Eligible women will receive neoadjuvant single fraction radiotherapy followed by surgery performed after one year

Predicting Breast Cancer With the BRAVE System

Recruiting now1 site

Breast cancer predominates among cancer diagnoses in Canadian women. It accounts for around 25% of new cases and contributes to 13% of all cancer-related deaths. In 2020, almost 27,400 Canadian women were diagnosed with breast cancer and 5,…

MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer

Recruiting nowPhase 11 site

The objective of this study is to demonstrate the feasibility of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered…

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Recruiting nowPhase 21 site

Advanced hormone positive (HR+), HER2 negative breast cancer continues to pose a challenge when patients have progressed on CDK4/6 inhibitor and endocrine therapy leaving limited treatment options. Antibody-drug conjugates (ADCs) such as sa…

Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer

Recruiting nowPhase 21 site

The objective of this study is to demonstrate the efficacy and response of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy…

Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE)

Recruiting now1 site

This is a prospective, open-label, within-patient clinical trial to determine the accuracy of Indocyanine green (ICG) guided sentinel lymph node biopsy (SLNB) compared to the standard dual-tracer SLNB in breast cancer patients who have had …

Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response

Recruiting now3 sites

This work explores the possibility of using ultrasound imaging and spectroscopy as a way of monitoring cell death, hence, tumour response to treatment. The hypothesis here is that it can be used as a way of monitoring early response to canc…

Three-Dimensional Ultrasound and Spectroscopy as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment

Opening soon1 site

The purpose of the study is to test the hypothesis that ultrasound imaging and spectroscopy may be used as a predictive marker of advanced tumour response to neoadjuvant treatment consisting of chemotherapy or concurrent chemotherapy-radiot…

BreastCancerPEP: A Six-Month Online Empowerment Program to Improve Mental and Physical Health in Women With Breast Cancer

Opening soon1 site

This study is evaluating a six-month, home-based Patient Empowerment Program (Breast Cancer PEP) for women receiving treatment for newly diagnosed invasive breast cancer. The program provides daily guidance on physical activity, arm and sho…

Using a Blood Test to Monitor Metastatic Breast Cancer Treatment

Recruiting now2 sites

The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.

Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings

Recruiting now1 site

The goal of this research study is to evaluate the performance of two experimental tests, namely Liquid Biopsy and Positron Emission Mammography (PEM) in women at high risk of breast cancer. The plan for this study is to assess whether find…

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Opening soonPhase 21 site

The goal of this clinical trial is to learn if the drug Sacituzumab govitecan (SG) reduces disease progression when used as a first-line treatment in adults with advanced triple-negative breast cancer (TNBC) who have not received prior trea…

SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

Opening soon1 site

The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer. Secondary objectives will be overall survival, progression-free survival and time to sw…

Questions fréquentes

Comment trouver un essai clinique (cancer du sein) près de chez moi au Canada ?

Utilisez la recherche gratuite de Beacon : entrez « cancer du sein », votre âge et votre lieu, et vous verrez les essais en recrutement triés par distance, chacun expliqué en langage clair — y compris les sites juste de l'autre côté de la frontière américaine. Beacon interroge le registre officiel complet et n'exige jamais de compte.

Participer à un essai clinique coûte-t-il de l'argent ?

Le traitement à l'étude et les examens liés à l'étude sont habituellement fournis sans frais, et certains essais aident avec les déplacements. Au Canada, votre régime provincial d'assurance maladie continue de couvrir vos soins courants — confirmez toujours les détails avec l'équipe de l'étude.

Puis-je quitter un essai clinique après y avoir adhéré ?

Oui. La participation est toujours volontaire et vous pouvez quitter un essai à tout moment, pour n'importe quelle raison, sans perdre vos soins médicaux habituels.

Suis-je admissible à ces essais ?

Chaque essai a ses propres critères d'admissibilité. Beacon traduit les critères de chaque essai en une liste en langage clair que vous pouvez passer en revue et apporter à votre médecin — seule l'équipe de l'étude peut confirmer votre admissibilité.